ABIOMED (ABMD) Impella Data Shows a Sharp Rebound in April - Jefferies
Tweet Send to a Friend
Jefferies analyst Raj Denhoy reiterated a Buy rating and $425.00 price target on ABIOMED (NASDAQ: ABMD) noting that his dataset ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
